These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22200869)

  • 1. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
    Ramaswamy B; Fiskus W; Cohen B; Pellegrino C; Hershman DL; Chuang E; Luu T; Somlo G; Goetz M; Swaby R; Shapiro CL; Stearns V; Christos P; Espinoza-Delgado I; Bhalla K; Sparano JA
    Breast Cancer Res Treat; 2012 Apr; 132(3):1063-72. PubMed ID: 22200869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
    Tu Y; Hershman DL; Bhalla K; Fiskus W; Pellegrino CM; Andreopoulou E; Makower D; Kalinsky K; Fehn K; Fineberg S; Negassa A; Montgomery LL; Wiechmann LS; Alpaugh RK; Huang M; Sparano JA
    Breast Cancer Res Treat; 2014 Jul; 146(1):145-52. PubMed ID: 24903226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
    Owonikoko TK; Ramalingam SS; Kanterewicz B; Balius TE; Belani CP; Hershberger PA
    Int J Cancer; 2010 Feb; 126(3):743-55. PubMed ID: 19621389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
    Rugo HS; Campone M; Amadori D; Aldrighetti D; Conte P; Wardley A; Villanueva C; Melisko M; McHenry MB; Liu D; Lee F; Pivot X
    Breast Cancer Res Treat; 2013 Jun; 139(2):411-9. PubMed ID: 23649189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
    Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
    Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
    Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI;
    Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
    Tryfonidis K; Boukovinas I; Xenidis N; Christophyllakis C; Papakotoulas P; Politaki E; Malamos N; Polyzos A; Kakolyris S; Georgoulias V; Mavroudis D;
    Breast; 2013 Dec; 22(6):1171-7. PubMed ID: 24091128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
    Cannita K; Paradisi S; Cocciolone V; Bafile A; Rinaldi L; Irelli A; Lanfiuti Baldi P; Zugaro L; Manetta R; Alesse E; Ricevuto E; Ficorella C
    Cancer Med; 2016 Sep; 5(9):2232-9. PubMed ID: 27416882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
    Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Kang YK
    Br J Cancer; 2016 May; 114(11):1185-90. PubMed ID: 27172248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
    Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
    Meng Q; Chen X; Sun L; Zhao C; Sui G; Cai L
    Mol Cell Biochem; 2011 Feb; 348(1-2):165-71. PubMed ID: 21082217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
    Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
    Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
    Lobo C; Lopes G; Baez O; Castrellon A; Ferrell A; Higgins C; Hurley E; Hurley J; Reis I; Richman S; Seo P; Silva O; Slingerland J; Tukia K; Welsh C; Glück S
    Breast Cancer Res Treat; 2010 Sep; 123(2):427-35. PubMed ID: 20585851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
    Chinnaiyan P; Chowdhary S; Potthast L; Prabhu A; Tsai YY; Sarcar B; Kahali S; Brem S; Yu HM; Rojiani A; Murtagh R; Pan E
    Neuro Oncol; 2012 Jan; 14(1):93-100. PubMed ID: 22028388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
    Goldstein LJ; Zhao F; Wang M; Swaby RF; Sparano JA; Meropol NJ; Bhalla KN; Pellegrino CM; Katherine Alpaugh R; Falkson CI; Klein P; Sledge GW
    Breast Cancer Res Treat; 2017 Sep; 165(2):375-382. PubMed ID: 28623430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
    Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
    Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.